Finding the way forward: Exploring post-stroke cognitive impairments and the therapeutic potential of the PDE4 inhibitor roflumilast

The research describes a clinical trial, in which Post Stroke Cognitive Impairment patients were included and received three months of treatment with either 100 micrograms roflumilast (a phosphodiesterase-4 inhibitor) or placebo. The research was followed by an open-label extension study, during which this placebo-group received roflumilast. The participants were tested with neuropsychological tests and daily digital home-based assessments.
The studies indicated that three-month treatment with roflumilast has the potential to improve memory function in PSCI patients. There might be benefits in psychomotor function and focused attention based on the digital assessments. No safety or tolerability issues were found. Roflumilast may be a promising treatment option for PSCI. Therefore, further research is necessary to confirm the current findings.
Moreover, greater emphasis should be placed on connecting objective cognitive deficits to the real-life challenges patients face. More ecologically valid methods to quantify these subjective complaints could include high-frequency testing and sensory-rich virtual reality (VR) environments, providing a more immersive and realistic way of assessing cognitive function with neuropsychological tests.